A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Официальное название

Post Marketing Surveillance Study for Jivi (Damoctocog Alfa Pegol) in Korean Patients With Hemophilia A

Обзор

In this study, researchers will observe and study the data from participants with hemophilia A who receive damoctocog alfa pegol as prescribed by their doctors. Participants will not receive any advice or changes to their healthcare during the study. Hemophilia A is a genetic bleeding disorder. It is caused by the lack of a protein called clotting factor 8 (FVIII) that helps blood to clot properly. Lack of FVIII can result in excessive blood loss or bleeding inside the body after being injured or having surgery. The study drug, damoctocog alfa pegol, can be used to prevent or treat bleeding episodes by replacing missing FVIII in the body of people with hemophilia A. It is already approved for people with hemophilia A who are at least 12 years old and have previously used other hemophilia A treatments. Through this study, researchers want to learn more about its safety in a real-world setting. The participants will receive damoctocog alfa pegol as prescribed by their doctors during routine practice according to the approved product information. The main purpose of this study is to learn more about how safe damoctocog alfa pegol is in Korean participants with hemophilia A who previously used other hemophilia A treatments. To do this, researchers will collect information about any medical problems participants have during their treatment. Data will be collected from December 2023 to March 2026 and cover a period of about 8 months for each participant. Data will come from participants' health records and information collected during their routine clinic visits. In this study, only available data from routine care will be collected. No visits or tests are required as part of this study.

Вмешательства

• Препарат Damoctocog-alfa-pegol (Jivi, BAY94-9027)
  Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.

Первичные конечные точки

• Occurrence of adverse events (AEs) [Срок оценки: Up to 36 weeks]
• Occurrence of Serious adverse events (SAEs) [Срок оценки: Up to 36 weeks]
• Occurrence of adverse reactions (ARs) [Срок оценки: Up to 36 weeks]
• Occurrence of Serious adverse reactions (SARs) [Срок оценки: Up to 36 weeks]
• Occurrence of adverse events of important identified risks (AESIs) [Срок оценки: Up to 36 weeks]
• Number of adverse events related to overdose [Срок оценки: Up to 36 weeks]
• Number of adverse events related to previously taken drugs and concomitant drugs [Срок оценки: Up to 36 weeks]

Вторичные конечные точки (6)

• Annualized number of reported total bleeds [Срок оценки: Up to 36 weeks]
• Difference in annualized total number of injections, injection frequency from previous FVIII products versus Jivi (damoctocog alfa pegol) [Срок оценки: Up to 36 weeks]
• Difference annualized total/average factor consumption (for overall, prophylaxis, bleeds(Intermittent prophylaxis), and other events) from previous FVIII products versus Jivi (damoctocog alfa pegol) [Срок оценки: Up to 36 months]
• Regimen selection determinants (physician and patient) [Срок оценки: Up to 36 weeks]
• Number of patients with 0 bleeds, and the difference in proportion comparing to previous prophylaxis treatment [Срок оценки: Up to 36 weeks]
• ABR during the study compared with ABR for previous FVIII products in the 12 months prior to enrollment into the study [Срок оценки: Up to 36 weeks]

Критерии участия

Критерии включения

• ≥12 years of age with hemophilia A
• Previously treated with FVIII concentrate(s) (plasma derived or recombinant)
• Patients who have been treated with Jivi (damoctocog alfa pegol) and those for whom the decision to initiate treatment with Jivi was made as per physician's routine treatment practice with any kind of treatment modality (on-demand, prophylaxis, etc.)
• Written informed consent from subject or legal representative; assent from subject when appropriate

Критерии исключения

• Contraindication according to the local authorized indication (including known hypersensitivity to the drug substance or any of its components (e.g., mouse or hamster protein))
• Patients participating in an investigational program with interventions outside of routine clinical practice
• Patients with any other diagnosis of bleeding/coagulation disorder other than hemophilia A
• Patients on immune tolerance induction treatment at the time of enrollment

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

South Korea · 1 центр

• Many Locations — Multiple Locations

Идентификаторы

NCT: NCT06222697 · 21278

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗